X-ray Imaging of Planetary Nebulae with Wolf-Rayet-type Central Stars: Detection of the Hot Bubble in NGC 40

We present the results of Chandra X-ray Observatory (CXO) observations of the planetary nebulae (PNs) NGC 40 and Hen 2-99. Both PNs feature late-type Wolf-Rayet central stars that are presently driving fast ~1000 km/s, massive winds into denser, slow-moving (~10 km/s) material ejected during recently terminated asymptotic giant branch (AGB) evolutionary phases. Hence, these observations provide key tests of models of wind-wind interactions in PNs. In NGC 40, we detect faint, diffuse X-ray emission distributed within a partial annulus that lies nested within a ~40'' diameter ring of nebulosity observed in optical and near-infrared images. Hen 2-99 is undetected. The inferred X-ray temperature (T_X ~10^6 K) and luminosity (L_X ~ 2 X 10^30 ergs/s) of NGC 40 are the lowest measured thus far for any PN displaying diffuse X-ray emission. These results, combined with the ring-like morphology of the X-ray emission from NGC 40, suggest that its X-ray emission arises from a ``hot bubble'' that is highly evolved and is generated by a shocked, quasi-spherical fast wind from the central star, as opposed to AGB or post-AGB jet activity. In constrast, the lack of detectable X-ray emission from Hen 2-99 suggests that this PN has yet to enter a phase of strong wind-wind shocks.Comment: 15 pages, 5 figures to appear in The Astrophysical Journa

Kinematic and morphological modeling of the bipolar nebula Sa2-237

We present [OIII]500.7nm and Halpha+[NII] images and long-slit, high resolution echelle spectra in the same spectral regions of Sa2--237, a possible bipolar planetary nebula. The image shows a bipolar nebula of about 34" extent, with a narrow waist, and showing strong point symmetry about the central object, indicating it's likely binary nature. The long slit spectra were taken over the long axis of the nebula, and show a distinct ``eight'' shaped pattern in the velocity--space plot, and a maximum projected outflow velocity of V=106km/s, both typical of expanding bipolar planetary nebulae. By model fitting the shape and spectrum of the nebula simultaneously, we derive the inclination of the long axis to be 70 degrees, and the maximum space velocity of expansion to be 308 km/s. Due to asymmetries in the velocities we adopt a new value for the system's heliocentric radial velocity of -30km/s. We use the IRAS and 21cm radio fluxes, the energy distribution, and the projected size of Sa2-237 to estimate it's distance to be 2.1+-0.37kpc. At this distance Sa2-237 has a luminosity of 340 Lsun, a size of 0.37pc, and -- assuming constant expansion velocity -- a nebular age of 624 years. The above radial velocity and distance place Sa2--237 in the disk of the Galaxy at z=255pc, albeit with somewhat peculiar kinematics.Comment: 10pp, 4 fig

Stellar evolution and nucleosynthesis of Post-AGB Stars

I discuss recent new models of post-Asymptotic Giant Branch stellar evolution. These models aim to clarify the evolutionary origin and status of a variety of hydrogen-deficient post-AGB stars such as central stars of planetary nebulae of Wolf-Rayet spectral type, PG1159 stars or Sakurai's object. Starting with AGB models with overshoot such stars can evolve through one of four distinct channels. Each of these channels has typical abundance patterns depending on the relative timing of the departure from the AGB and the occurrence of the last thermal pulse. I discuss the responsible mechanisms and observational counterparts.Comment: 9 pages, 1 figure, conference paper, workshop "Post-AGB objects (proto-planetary nebulae) as a phase of stellar evolution", Jul 5-7, 2000, Torun, Poland, to appear in Ap&S

Different Pattern of Immunoglobulin Gene Usage by HIV-1 Compared to Non-HIV-1 Antibodies Derived from the Same Infected Subject

A biased usage of immunoglobulin (Ig) genes is observed in human anti-HIV-1 monoclonal antibodies (mAbs) resulting probably from compensation to reduced usage of the VH3 family genes, while the other alternative suggests that this bias usage is due to antigen requirements. If the antigen structure is responsible for the preferential usage of particular Ig genes, it may have certain implications for HIV vaccine development by the targeting of particular Ig gene-encoded B cell receptors to induce neutralizing anti-HIV-1 antibodies. To address this issue, we have produced HIV-1 specific and non-HIV-1 mAbs from an infected individual and analyzed the Ig gene usage. Green-fluorescence labeled virus-like particles (VLP) expressing HIV-1 envelope (Env) proteins of JRFL and BaL and control VLPs (without Env) were used to select single B cells for the production of 68 recombinant mAbs. Ten of these mAbs were HIV-1 Env specific with neutralizing activity against V3 and the CD4 binding site, as well as non-neutralizing mAbs to gp41. The remaining 58 mAbs were non-HIV-1 Env mAbs with undefined specificities. Analysis revealed that biased usage of Ig genes was restricted only to anti-HIV-1 but not to non-HIV-1 mAbs. The VH1 family genes were dominantly used, followed by VH3, VH4, and VH5 among anti-HIV-1 mAbs, while non-HIV-1 specific mAbs preferentially used VH3 family genes, followed by VH4, VH1 and VH5 families in a pattern identical to Abs derived from healthy individuals. This observation suggests that the biased usage of Ig genes by anti-HIV-1 mAbs is driven by structural requirements of the virus antigens rather than by compensation to any depletion of VH3 B cells due to autoreactive mechanisms, according to the gp120 superantigen hypothesis

A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals

A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most donors through a limited number of specificities (1–2 per donor). The major targets recognized are an epitope defined by the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera

Inducing Cross-Clade Neutralizing Antibodies against HIV-1 by Immunofocusing

Background: Although vaccines are important in preventing viral infections by inducing neutralizing antibodies (nAbs), HIV-1 has proven to be a difficult target and escapes humoral immunity through various mechanisms. We sought to test whether HIV-1 Env mimics may serve as immunogens. Methodology/Principal Findings: Using random peptide phage display libraries, we identified the epitopes recognized by polyclonal antibodies of a rhesus monkey that had developed high-titer, broadly reactive nAbs after infection with a simianhuman immunodeficiency virus (SHIV) encoding env of a recently transmitted HIV-1 clade C (HIV-C). Phage peptide inserts were analyzed for conformational and linear homology using computational analysis; some peptides mimicked various domains of the original HIV-C Env, such as conformational V3 loop epitopes and the conserved linear region of the gp120 C-terminus. Next, we devised a novel prime/boost strategy to test the immunogenicity of such phage-displayed peptides and primed mice only once with HIV-C gp160 DNA followed by boosting with mixtures of recombinant phages. Conclusions/Significance: This strategy, which was designed to focus the immune system on a few Env epitopes (immunofocusing), not only induced HIV-C gp160 binding antibodies and cross-clade nAbs, but also linked a conserved HIV Env region for the first time to the induction of nAbs: the C-terminus of gp120. The identification of conserved antige

Molecular Evolution of HIV-1 CRF01_AE Env in Thai Patients

BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1. A circulating recombinant form of HIV-1, CRF01_AE, is prevalent throughout Southeast Asia; however, only limited information regarding the immunological characteristics of CRF01_AE Env is currently available. In this study, we attempted to examine the evolutionary pattern of CRF01_AE Env under the selection pressure of host immune responses. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood samples were collected periodically over 3 years from 15 HIV-1-infected individuals residing in northern Thailand, and amplified env genes from the samples were subjected to computational analysis. The V5 region of gp120 showed highest variability in several samples over 3 years, whereas the V1/V2 and/or V4 regions of gp120 also showed high variability in many samples. In addition, the N-terminal part of the C3 region of gp120 showed highest amino acid diversity among the conserved regions of gp120. Chronological changes in the numbers of amino acid residues in gp120 variable regions and potential N-linked glycosylation (PNLG) sites are involved in increasing the variability of Env gp120. Furthermore, the C3 region contained several amino acid residues potentially under positive selection, and APOBEC3 family protein-mediated G to A mutations were frequently detected in such residues. CONCLUSIONS/SIGNIFICANCE: Several factors, including amino acid substitutions particularly in gp120 C3 and V5 regions as well as changes in the number of PNLG sites and in the length of gp120 variable regions, were revealed to be involved in the molecular evolution of CRF01_AE Env. In addition, a similar tendency was observed between CRF01_AE and subtype C Env with regard to the amino acid variation of gp120 V3 and C3 regions. These results may provide important information for understanding the immunological characteristics of CRF01_AE Env

International Network for Comparison of HIV Neutralization Assays: The NeutNet Report

BACKGROUND: Neutralizing antibody assessments play a central role in human immunodeficiency virus type-1 (HIV-1) vaccine development but it is unclear which assay, or combination of assays, will provide reliable measures of correlates of protection. To address this, an international collaboration (NeutNet) involving 18 independent participants was organized to compare different assays. METHODS: Each laboratory evaluated four neutralizing reagents (TriMab, 447-52D, 4E10, sCD4) at a given range of concentrations against a panel of 11 viruses representing a wide range of genetic subtypes and phenotypes. A total of 16 different assays were compared. The assays utilized either uncloned virus produced in peripheral blood mononuclear cells (PBMCs) (virus infectivity assays, VI assays), or their Env-pseudotyped (gp160) derivatives produced in 293T cells (PSV assays) from molecular clones or uncloned virus. Target cells included PBMC and genetically-engineered cell lines in either a single- or multiple-cycle infection format. Infection was quantified by using a range of assay read-outs that included extracellular or intracellular p24 antigen detection, RNA quantification and luciferase and beta-galactosidase reporter gene expression. FINDINGS: PSV assays were generally more sensitive than VI assays, but there were important differences according to the virus and inhibitor used. For example, for TriMab, the mean IC50 was always lower in PSV than in VI assays. However, with 4E10 or sCD4 some viruses were neutralized with a lower IC50 in VI assays than in the PSV assays. Inter-laboratory concordance was slightly better for PSV than for VI assays with some viruses, but for other viruses agreement between laboratories was limited and depended on both the virus and the neutralizing reagent. CONCLUSIONS: The NeutNet project demonstrated clear differences in assay sensitivity that were dependent on both the neutralizing reagent and the virus. No single assay was capable of detecting the entire spectrum of neutralizing activities. Since it is not known which in vitro assay correlates with in vivo protection, a range of neutralization assays is recommended for vaccine evaluation